TargetAMD 1.0
Partner/Funding
The project TargetAMD was funded by the European Commission in the context of the Seventh Framework Programme classified to the topic health.
TargetAMD 1.0
The project TargetAMD was funded by the European Commission in the context of the Seventh Framework Programme classified to the topic health.
TargetAMD 1.0
Age-related Macular Degeneration (AMD) is a disease of the light-sensitive part of the eye (retina) that is responsible for vision. AMD is a major cause of blindness in elderly people and due to the aging population, it has been referred to as a “time bomb” in society.
TargetAMD 1.0
To continue therapy development, the private foundation Provisu agreed to financially support the project in two phases; the pre-clinical phase was thought to collect pre-clinical data required to get clinical study approval and the clinical phase will comprise the phase Ib/IIa clinical study. Phase I lasted from March 1, 2020 to April 30, 2023, while phase II will start as soon as we will get the approval to perform the clinical trial, assumed for fall 2023.